Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lübbert

Showing results (61-70 of 248) with videos related to

Pageof 25
Sort By:
Current Pharmaceutical Biotechnology|November 2, 2006
DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AMLClaudia I Müller, Björn Rüter, H Phillip Koeffler, et al.
The Lancet. Haematology|March 31, 2019
10-day vs 5-day decitabine: equivalence cannot be concludedGerwin Huls, Stefan Suciu, Pierre Wijermans, et al.
Leukemia Research|June 19, 2004
The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromesJoan van den Bosch, Michael Lübbert, Gregor Verhoef, et al.
Cancers|December 11, 2022
Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and TreatmentAsmaa Elrakaybi, Dietrich A Ruess, Michael Lübbert, et al.
Journal of Cellular Biochemistry|July 10, 2008
Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapyMichael Lübbert, Carsten Müller-Tidow, Wolf-Karsten Hofmann, et al.
Blood|August 5, 2006
CXCR4 is a prognostic marker in acute myelogenous leukemiaAnke C Spoo, Michael Lübbert, William G Wierda, et al.
BMC Cancer|December 18, 2015
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cellsGabriele Greve, Insa Schiffmann, Dietmar Pfeifer, et al.
The Cochrane Database of Systematic Reviews|August 7, 2018
Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL))Yasemin Küley-Bagheri, Karl-Anton Kreuzer, Ina Monsef, et al.
Annals of Hematology|December 17, 2013
Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosisHelga Maurer, Peter Haas, Tobias Wengenmayer, et al.
Leukemia Research|January 25, 2014
The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cellsAitomi Essig, Jesus Duque-Afonso, Sven Schwemmers, et al.
Pageof 25

Showing results (61-70 of 248) with videos related to

Sort By:
Pageof 25
Current Pharmaceutical Biotechnology|November 2, 2006
DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AMLClaudia I Müller, Björn Rüter, H Phillip Koeffler, et al.
The Lancet. Haematology|March 31, 2019
10-day vs 5-day decitabine: equivalence cannot be concludedGerwin Huls, Stefan Suciu, Pierre Wijermans, et al.
Leukemia Research|June 19, 2004
The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromesJoan van den Bosch, Michael Lübbert, Gregor Verhoef, et al.
Cancers|December 11, 2022
Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and TreatmentAsmaa Elrakaybi, Dietrich A Ruess, Michael Lübbert, et al.
Journal of Cellular Biochemistry|July 10, 2008
Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapyMichael Lübbert, Carsten Müller-Tidow, Wolf-Karsten Hofmann, et al.
Blood|August 5, 2006
CXCR4 is a prognostic marker in acute myelogenous leukemiaAnke C Spoo, Michael Lübbert, William G Wierda, et al.
BMC Cancer|December 18, 2015
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cellsGabriele Greve, Insa Schiffmann, Dietmar Pfeifer, et al.
The Cochrane Database of Systematic Reviews|August 7, 2018
Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL))Yasemin Küley-Bagheri, Karl-Anton Kreuzer, Ina Monsef, et al.
Annals of Hematology|December 17, 2013
Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosisHelga Maurer, Peter Haas, Tobias Wengenmayer, et al.
Leukemia Research|January 25, 2014
The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cellsAitomi Essig, Jesus Duque-Afonso, Sven Schwemmers, et al.
Pageof 25